2.Reversible pulmonary arterial hypertension related to dasatinib in the treatment for chronic myelogenous leukemia: a case report and literature review.
Bingcheng LIU ; Ying WANG ; Yingchang MI ; Jianxiang WANG
Chinese Journal of Hematology 2014;35(7):581-586
OBJECTIVETo study the clinical features and prognosis of pulmonary arterial hypertension associated with dasatinib.
METHODSTo present a case of pulmonary arterial hypertension (PAH) associated with long-term exposure to dasatinib and review the related literatures.
RESULTSA 23-year-old female with chronic myelogenous leukemia was treated with dasatinib at a dosage of 140 mg/d after failure of imatinib treatment and achieved complete cytogenetic response. The patient was presented with exertional dyspnea after 35 months of administration with dasatinib. The electrocardiogram showed right ventricular hypertrophy and right axis deviation; transthoracic Doppler echocardiography documented a reduction in diameters of left heart chambers with normal systolic left ventricular function, right heart chambers and pulmonary trunk dilatation, an estimated pulmonary arterial pressure of 114 mmHg; Computed tomography showed thickened pulmonary artery. PAH related to dasatinib was diagnosed and dasatinib was permanently discontinued. The symptom of dyspnea disappeared quickly after withdrawal of dasatinib. The heart structure and pulmonary arterial pressure completely recovered after 7 months of dasatinib discontinuation.
CONCLUSIONPAH is a rare adverse effect of dasatinib treatment. Echocardiograhpy, as a non-invasive screening test for PAH, should be performed before starting dasatinib treatment and repeated during the administration with dasatinib. Dasatinib should be withdrawn permanently in patients with PAH.
Dasatinib ; Female ; Humans ; Hypertension, Pulmonary ; chemically induced ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; drug therapy ; Prognosis ; Pyrimidines ; adverse effects ; Thiazoles ; adverse effects ; Young Adult
3.Voriconazole in an infant with cryptococcal meningitis.
Yin-zhong SHEN ; Jiang-rong WANG ; Hong-zhou LU
Chinese Medical Journal 2008;121(3):286-288
4.Anterior Ischemic Optic Neuropathy Associated with Udenafil.
Korean Journal of Ophthalmology 2012;26(3):235-238
We report a case of anterior ischemic optic neuropathy associated with udenafil. A 54-year-old male presented with an acute onset visual field defect of the right eye after udenafil use. Examination revealed a relative afferent pupillary defect and a swollen disc. Automated visual fields revealed an enlarged blind spot and a narrowed visual field. Fluorescein angiography revealed both an inferior choroidal filling delay and an inferior sector filling delay of the optic disc in the arteriovenous phase as well as diffuse leakage of the optic disc in the late phase. Optical coherent tomography revealed increased thickness of the retinal nerve fiber layer, especially in the area of the inferior disc. The patient was counseled to discontinue the use of udenafil and to monitor his blood pressure regularly. The disc swelling was resolved with residual optic atrophy one month after discontinuing the use of udenafil.
Acute Disease
;
Choroid/*pathology
;
Humans
;
Male
;
Middle Aged
;
Optic Neuropathy, Ischemic/*chemically induced/diagnosis
;
Phosphodiesterase 5 Inhibitors/adverse effects
;
Pyrimidines/*adverse effects
;
Sulfonamides/*adverse effects
;
Tomography, Optical Coherence
;
Visual Fields
5.Clinical efficacy of rosuvastatin in lipid management in Chinese patients in Hong Kong.
Vivian W Y LEE ; T S CHAU ; Vice P H LEUNG ; Kenneth K C LEE ; Brian TOMLINSON
Chinese Medical Journal 2009;122(23):2814-2819
BACKGROUNDRosuvastatin has been claimed to be more potent than other statins in its ability to lower the low-density lipoprotein (LDL) cholesterol levels. This study aimed to investigate the clinical efficacy of rosuvastatin in LDL cholesterol lowering therapy for new or switched hyperlipidaemic Chinese patients.
METHODSThis study was a retrospective one in patients who took rosuvastatin in the outpatient clinics of Prince of Wales Hospital during the period of July 1, 2004 to June 30, 2005. The prescribing pattern, the utilization pattern and the side effect profile were recorded. Attainment of lipid goals for each patient was assessed according to the National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III guidelines.
RESULTSA total of 261 Chinese patients (mean age (64.8 +/- 12) years; 55.6% male) were recruited into the study. The mean LDL-cholesterol level was (3.50 +/- 1.29) mmol/L prior to Rosuvastatin and (2.30 +/- 1.73) mmol/L after Rosuvastatin treatment (P < 0.0001). Rosuvastatin raised the LDL-cholesterol goal achievement rate from 28.0% to 74.3% in all patients combined (P < 0.0001) and from 11.0% to 79.0% for statin naive patients (P < 0.0001). Approximately 4% of patients developed side effects including myalgia, elevated liver enzymes, and dizziness.
CONCLUSIONRosuvastatin was effective in improving LDL-cholesterol goal attainment and lowering LDL-cholesterol and triglyceride (TG) levels in either newly started or switched patients.
Adult ; Aged ; Cholesterol, LDL ; blood ; Female ; Fluorobenzenes ; adverse effects ; therapeutic use ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; therapeutic use ; Male ; Middle Aged ; Pyrimidines ; adverse effects ; therapeutic use ; Retrospective Studies ; Rosuvastatin Calcium ; Sulfonamides ; adverse effects ; therapeutic use
6.A Case of Pseudomembranous Colitis after Voriconazole Therapy.
Jae Cheol KWON ; Min Kyu KANG ; Si Hyun KIM ; Su Mi CHOI ; Hee Je KIM ; Woo Sung MIN ; Dong Gun LEE
Yonsei Medical Journal 2011;52(5):863-865
This is a case report on a 35-year-old man with acute myelogenous leukemia who presented fever and intermittent mucoid loose stool to the emergency center. He had been taking voriconazole for invasive pulmonary aspergillosis. The flexible sigmoidoscopy was consistent with the diagnosis of pseudomembranous colitis.
Adult
;
Antifungal Agents/*adverse effects
;
Enterocolitis, Pseudomembranous/*chemically induced/pathology
;
Humans
;
Invasive Pulmonary Aspergillosis/complications/drug therapy
;
Leukemia, Myeloid, Acute/complications
;
Male
;
Opportunistic Infections/complications/drug therapy
;
Pyrimidines/*adverse effects
;
Triazoles/*adverse effects
7.Bilateral masculine mastoplasia associated with imatinib mesylate: a case report and literature review.
Dan ZHAO ; Gaoxiang WANG ; Chunrui LI ; Li MENG
Journal of Huazhong University of Science and Technology (Medical Sciences) 2011;31(1):145-146
Adult
;
Antineoplastic Agents
;
adverse effects
;
therapeutic use
;
Benzamides
;
Gynecomastia
;
chemically induced
;
Humans
;
Imatinib Mesylate
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
;
drug therapy
;
Male
;
Piperazines
;
adverse effects
;
therapeutic use
;
Pyrimidines
;
adverse effects
;
therapeutic use
8.Reversible Dysphasia and Statins.
Journal of Korean Medical Science 2012;27(4):458-459
This paper presents a case of reversible dysphasia occurring in a patient prescribed atorvastatin in combination with indapamide. A milder dysphasia recurred with the prescription of rosuvastatin and was documented on clinical examination. This resolved following cessation of rosuvastatin. The case highlights both a need for a wider understanding of potential drug interactions through the CYP 450 system and for an increased awareness, questioning and reporting of drug side-effects.
Anticholesteremic Agents/adverse effects/*therapeutic use
;
Antihypertensive Agents/therapeutic use
;
Anxiety/diagnosis
;
Aphasia/diagnosis/*etiology
;
Cytochrome P-450 Enzyme System/metabolism
;
Depression/diagnosis
;
Drug Interactions
;
Female
;
Fluorobenzenes/adverse effects/*therapeutic use
;
Heptanoic Acids/adverse effects/*therapeutic use
;
Humans
;
Hypercholesterolemia/drug therapy
;
Indapamide/therapeutic use
;
Middle Aged
;
Pyrimidines/adverse effects/*therapeutic use
;
Pyrroles/adverse effects/*therapeutic use
;
Sulfonamides/adverse effects/*therapeutic use
9.Efficacy and safety analysis of interferon combined with imatinib in treating chronic myeloid leukemia.
Yang LIU ; Er-Ning BAO ; Wen-Wen ZHONG ; Xue-Chun LU ; Hong-Li ZHU
Journal of Experimental Hematology 2014;22(2):304-309
Imatinib has been recognized as the frontline therapy drug in chronic myeloid leukemia (CML), however, only limited patients could achieve complete molecular remission (CMR). Recent clinical and basic proofs indicated an improved treatment outcome by the combination of interferon and Imatinib. This study was purposed to evaluated systematically the efficacy and safety of interferon plus Imatinib in patients with CML. Data from relative clinical trials were from clinical trial of gov and Cochrane Collaboration. A comprehensive literature search was performed from data bases such as pubMed and EM. The results indicated that 7 clinical trials and 12 research papers met the criteria enrolled in study, included 697 cases in total. The combination group had higher complete cytogenetic remission (CCgR) rate than imatinib alone at 6 months (58% vs 42%; P = 0.0001) and 12 months (74% vs 68%; P = 0.004). The major molecular remission (MMR) rate was also higher in the combination group at 6 months (58% vs 34%; P = 0.0001) and 12 months (66% vs 47%; P < 0.0001). Furthermore, compared with single drug, the combination group had superior CMR rate at 6 months (13% vs 2%; P = 0.0002) and 12 months (14% vs 5%; P = 0.0009). The major adverse effects of combination therapy were rash, asthenia, edema and musculoskeletal events, and combination therapy was more prone to inducing neutropenia, thrombocytopenia and mild anemia. It is concluded that compared with Imatinib alone, the combination of interferon and Imatinib has better clinical efficacy in treating CML with earlier cytogenetic and molecular remission. It is also a safe therapy in spite of slightly weaker tolerance than single drug therapy.
Antineoplastic Combined Chemotherapy Protocols
;
adverse effects
;
therapeutic use
;
Benzamides
;
administration & dosage
;
adverse effects
;
Humans
;
Imatinib Mesylate
;
Interferons
;
administration & dosage
;
adverse effects
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
;
drug therapy
;
Piperazines
;
administration & dosage
;
adverse effects
;
Pyrimidines
;
administration & dosage
;
adverse effects
;
Treatment Outcome
10.The Clinical Observation with Ruxolitinib as Graft-Versus-Host Disease Prophylaxis for Children with Thalassemia after Unrelated or Haploidentical Allo-Hematopoietic Stem Cell Transplantation.
Ya-Mei CHEN ; Xiu-Li HONG ; Jin-Zong LIN ; Jie SHI ; Quan-Yi LU
Journal of Experimental Hematology 2022;30(5):1586-1589
OBJECTIVE:
To retrospectively analyze the efficacy and safety of ruxolitinib therapy for children with thalassemia after unrelated or haploidentical stem cell transplantation.
METHODS:
From March 2020 to March 2021, 22 patients received successfully allogeneic hematopoietic stem cell transplantation in the Zhongshan Hospital of Xiamen University, from +30 to 100 days,those patients received ruxolitinib therapy (2.5 mg, twice daily) and all adverse reactions were observed, include aGVHD, cGVHD, CMV and EBV infection.
RESULTS:
22 patients underwent allogeneic stem cell transplantation, 5 patients were diagnosed as aGVHD, 3 patients had grade I-II skin GVHD and 2 patients had grade II intestinal GVHD, those patients were cured. All patients were followed up for more than 21 weeks, 4 cases developed cGVHD, including 3 cases of localized liver GVHD and 1 case of pulmonary GVHD, those were relieved after active treatment. 8 patients had elevated EBV copies (>3×103/ml), and 3 patients had increased CMV copies, the patients recovered after immunosuppressant and antiviral treatment. There was no CMV infection and EBV related post-transplantant lymphoproliferative disorders(PTLD), and no transplant related deaths.
CONCLUSION
Ruxolitinib can effectively reduce the incidence and severity of GVHD without affecting the hematopoietic recovery, and improve the survival status of thalassemia children after transplantation.
Antiviral Agents/therapeutic use*
;
Child
;
Graft vs Host Disease/prevention & control*
;
Hematopoietic Stem Cell Transplantation/adverse effects*
;
Humans
;
Immunosuppressive Agents/therapeutic use*
;
Nitriles
;
Pyrazoles
;
Pyrimidines
;
Retrospective Studies
;
Thalassemia